论文部分内容阅读
在本次论坛的媒体座谈交流会上,南京医药股份有限公司董事长周耀平接受了媒体提问,对我国在经方制剂上现阶段面临的挑战及发展经方产业今后的规划等问题作出了解答。记者:与国外相比,我国在经方制剂上面临的挑战是什么?周耀平:中医药源于中国,经方和经方制剂也源于中国,但是由于种种原因,我国经方及经方制剂的研究开发和产业化已经落后于日本、德国和韩国等国家。从全球格局来看,包括药
At the forum’s media symposium, Zhou Yaoping, chairman of Nanjing Pharmaceutical Co., Ltd., accepted the media’s questions and answered questions concerning the challenges faced by China in the formulation of the preparations for the parties and the future planning of the development of the industry. . Reporter: Compared with foreign countries, what are the challenges faced by China in formulating preparations? Zhou Yaoping: Chinese medicine originates from China, and formulae from the Fangfang and Jingfang formulas also originate from China, but due to various reasons, the Chinese economy and the economic side The research and development and industrialization of preparations have lagged behind Japan, Germany and South Korea. From a global perspective, including drugs